Stock RVNC REVANCE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Delayed Nasdaq
Other stock markets
 03:52:44 2024-04-18 pm EDT 		5-day change 1st Jan Change
3.78 USD +0.53% Intraday chart for Revance Therapeutics, Inc. -15.09% -57.11%
Apr. 12 Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting CI
Mar. 12 Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
AQ
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives
AQ
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
BU
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
CI
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data
DJ
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation
AQ
Revance Therapeutics Prices $100 Million Public Offering
MT
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
BU
Revance Announces Proposed Public Offering of Common Stock
BU
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating
MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating
MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating
MT
Transcript : Revance Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M
MT
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
BU
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024
CI
Revance Therapeutics, Inc. Announces Executive Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVNC Stock
  4. News Revance Therapeutics, Inc.